Heidbreder Christian 4

What Happened
Christian Heidbreder, Chief Scientific Officer of Indivior Pharmaceuticals (INDV), sold 18,586 shares on July 10, 2026 at $41.14 per share, generating proceeds of approximately $764,628. This was a sale (not a purchase) and was executed pursuant to a pre-established trading arrangement.

Key Details

• Transaction date: July 10, 2026; Price: $41.14 per share; Total proceeds: ~$764,628
• Transaction type: Sale (open market) reported on Form 4 filed July 13, 2026
• Shares owned after transaction: Not specified in the information provided in this summary
• Footnote: Sale effected under a Rule 10b5-1 trading plan adopted by Heidbreder on March 13, 2026
• Filing timeliness: Form 4 filed July 13, 2026 for a July 10 transaction; no late-filing flag was provided in the supplied data

Context
Sales executed under Rule 10b5-1 plans are typically pre-scheduled and are common among executives to systematically reduce holdings or diversify; they do not, by themselves, indicate insider sentiment about the company’s prospects. Purchases are generally more informative about confidence, while routine sales like this are often administrative or portfolio-management related.